AdvisorShares Psychedelics ETF Rating $25.27 +0.02 (+0.08%) As of 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsBuy This Stock AdvisorShares Psychedelics ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.PSIL Aggregate RatingModerate Buy 2.63Holdings in PSIL have an aggregate rating of Moderate Buy based on 235 analyst ratings issued in the past year covering 20 companies (85.8% of the portfolio).PSIL Aggregate Price Target$25.27High Prediction$25.27Average Prediction$25.27Low Prediction$25.27Holdings in PSIL have an aggregate price target of $25.27 and a range of $25.27 to $25.27 covering 20 companies (85.8% of the portfolio).PSIL Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy1 Buy rating(s)Moderate Buy14 Moderate Buy rating(s)Hold3 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell2 Strong Sell rating(s) Ratings for Stocks Held by AdvisorShares Psychedelics ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 20 PSIL Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings13.90%ATAIAtai Beckley$7.26+0.1%3.7772 of 5 stars2.20$10.56 45.4%15Positive NewsEarnings ReportAnalyst DowngradeShort Interest Decrease12.09%DFTXDefinium Therapeutics$42.63-2.9%3.0347 of 5 stars3.00$62.14 45.8%19Trending NewsAnalyst ForecastAnalyst RevisionGap Down9.84%CMPSCompass Pathways$13.45+1.2%2.685 of 5 stars2.88$23.36 73.7%17Analyst Revision5.26%RLMDRelmada Therapeutics$4.80+1.1%2.2595 of 5 stars2.75$12.00 150.0%8Analyst Revision5.09%NBIXNeurocrine Biosciences$152.72+1.3%4.9877 of 5 stars2.88$200.86 31.5%24Analyst Downgrade4.78%GHRSGH Research$29.49+4.6%3.216 of 5 stars2.67$45.00 52.6%12Analyst Revision4.73%ANROAlto Neuroscience$32.14-0.5%1.5234 of 5 stars2.55$36.63 14.0%11News CoverageEarnings ReportAnalyst ForecastHigh Trading Volume4.61%NRXPNRx Pharmaceuticals$3.27-2.1%2.3185 of 5 stars2.50$34.50 955.0%6News CoverageEarnings ReportUpcoming Earnings4.44%ABBVAbbVie$249.20-0.6%4.9073 of 5 stars2.88$275.50 10.6%26Trending NewsAnalyst ForecastAnalyst Revision4.08%ALKSAlkermes$49.06-0.8%3.1696 of 5 stars2.72$54.56 11.2%18Positive News3.83%JNJJohnson & Johnson$260.44-0.6%4.8024 of 5 stars2.80$268.22 3.0%25Trending News3.28%STIMNeuronetics$3.30+8.9%4.053 of 5 stars2.50$4.50 36.4%4Earnings ReportAnalyst Forecast2.82%SUPNSupernus Pharmaceuticals$48.27+2.4%4.261 of 5 stars2.71$62.83 30.2%72.22%NEUPNeuphoria Therapeutics$3.87+1.0%2.3768 of 5 stars2.00$21.00 442.6%4Short Interest Increase1.47%LLYEli Lilly and Company$1,182.24-2.2%4.7297 of 5 stars2.83$1,292.18 9.3%30Trending NewsAnalyst DowngradeInsider TradeAnalyst Revision0.93%KTTAPasithea Therapeutics$0.48+0.5%3.7866 of 5 stars2.67$3.00 524.3%3Positive NewsEarnings Report0.92%PBMPsyence Biomedical$3.48-2.2%1.4247 of 5 stars1.001Positive News0.72%SILOSilo Pharma$3.20-0.6%0.5769 of 5 stars1.001Earnings Report0.40%IXHLIncannex Healthcare$3.28+3.8%2.7009 of 5 stars2.00$18.00 448.8%2Positive News0.38%IGCIGC Pharma$0.30+1.3%2.0872 of 5 stars2.50$5.50 1,746.9%2Earnings ReportHigh Trading Volume This page (NYSEARCA:PSIL) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredCentral banks bought 710 tonnes - this fund pays monthlyGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredYour 10X AI demo is starting…Keith Kaplan, the AI expert behind tools used by more than 100000 investors, built his models with an investme...TradeSmith | SponsoredWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredWho Really Gets Rich from IPOs?Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AdvisorShares Psychedelics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share AdvisorShares Psychedelics ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
